Cargando…

From lab to mass production: a policy for enabling the licensing of mRNA vaccines

Using the South African vaccine technology transfer hub supported by the WHO as an example, we show that the know-how needed to move mRNA vaccines from prototype to mass-production acts as an invisible barrier to market entry of mRNA vaccines. Overcoming this barrier relies on scarce human capital....

Descripción completa

Detalles Bibliográficos
Autores principales: Panagopoulos, Andreas, Sideri, Katerina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233741/
https://www.ncbi.nlm.nih.gov/pubmed/37275488
http://dx.doi.org/10.3389/fpubh.2023.1151713
_version_ 1785052322242494464
author Panagopoulos, Andreas
Sideri, Katerina
author_facet Panagopoulos, Andreas
Sideri, Katerina
author_sort Panagopoulos, Andreas
collection PubMed
description Using the South African vaccine technology transfer hub supported by the WHO as an example, we show that the know-how needed to move mRNA vaccines from prototype to mass-production acts as an invisible barrier to market entry of mRNA vaccines. Overcoming this barrier relies on scarce human capital. In view of this scarcity and in preparation for the next pandemic, we propose broadening the scope of an existing WHO program, the WHO Academy, so that it coordinates knowledge diffusion initiatives by forming a systematized repository of know-how and a register of experts. As we explain, this proposal has an advantage in overcoming barriers to entry over current approaches of know-how acquisition.
format Online
Article
Text
id pubmed-10233741
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102337412023-06-02 From lab to mass production: a policy for enabling the licensing of mRNA vaccines Panagopoulos, Andreas Sideri, Katerina Front Public Health Public Health Using the South African vaccine technology transfer hub supported by the WHO as an example, we show that the know-how needed to move mRNA vaccines from prototype to mass-production acts as an invisible barrier to market entry of mRNA vaccines. Overcoming this barrier relies on scarce human capital. In view of this scarcity and in preparation for the next pandemic, we propose broadening the scope of an existing WHO program, the WHO Academy, so that it coordinates knowledge diffusion initiatives by forming a systematized repository of know-how and a register of experts. As we explain, this proposal has an advantage in overcoming barriers to entry over current approaches of know-how acquisition. Frontiers Media S.A. 2023-05-18 /pmc/articles/PMC10233741/ /pubmed/37275488 http://dx.doi.org/10.3389/fpubh.2023.1151713 Text en Copyright © 2023 Panagopoulos and Sideri. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Panagopoulos, Andreas
Sideri, Katerina
From lab to mass production: a policy for enabling the licensing of mRNA vaccines
title From lab to mass production: a policy for enabling the licensing of mRNA vaccines
title_full From lab to mass production: a policy for enabling the licensing of mRNA vaccines
title_fullStr From lab to mass production: a policy for enabling the licensing of mRNA vaccines
title_full_unstemmed From lab to mass production: a policy for enabling the licensing of mRNA vaccines
title_short From lab to mass production: a policy for enabling the licensing of mRNA vaccines
title_sort from lab to mass production: a policy for enabling the licensing of mrna vaccines
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233741/
https://www.ncbi.nlm.nih.gov/pubmed/37275488
http://dx.doi.org/10.3389/fpubh.2023.1151713
work_keys_str_mv AT panagopoulosandreas fromlabtomassproductionapolicyforenablingthelicensingofmrnavaccines
AT siderikaterina fromlabtomassproductionapolicyforenablingthelicensingofmrnavaccines